Added to YB: 2026-06-29
Pitch date: 2026-06-25
ARGX [neutral]
argenx SE
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Market Cap
EUR 55.6B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
38.93
P/E
39.77
EV/Sales
10.80
Sector
Biotechnology
Category
growth
Argenx (ARGX Belgium): Myositis could become the next major chapter for Vyvgart
ARGX (overview): Vyvgart maker eyeing myositis as next growth chapter, Phase III data due Q3. Phase II showed strong, fast efficacy in muscle strength/function w/ biomarker support. Mgmt splitting IMNM vs dermatomyositis for regulatory flexibility; durable LTE data. Part of Vision 2030 rheumatology push leveraging existing infra. Pipeline (empasiprubart, adimanebart) adds diversification. High expectations post strong run.
Read full article (2 min)